Form 4: IGC Pharma CEO Reports Stock Transaction
Insider Transaction (Form 4)
Ram Mukunda, CEO and a Director of IGC Pharma, Inc., reported multiple transactions in common stock on September 25, 2026.
Summary
- Bona fide gift: disposed of 100,000 Common Stock on September 25, 2026; holds 6,775,563 after (Direct).
- Bona fide gift: disposed of 100,000 Common Stock on September 25, 2026; holds 6,675,563 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Ram Mukunda — Director, Officer (CEO)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-25 | Bona fide gift | Common Stock | 100,000 | — | — | 6,775,563 |
| 2026-09-25 | Bona fide gift | Common Stock | 100,000 | — | — | 6,675,563 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-25 | Bona fide gift (100,000 shares) |
| 2026-09-25 | Bona fide gift (100,000 shares) |
Keywords
insider transaction, Form 4, IGC, IGC Pharma, Inc., neutral, Ram Mukunda
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.